
    
      EXIT COVID-19 is a multi-center, randomized, double-blinded, placebo-controlled trial that
      will enroll 60 COVID-19 patients with moderate-to-severe ARDS at three research sites across
      the U.S. The primary efficacy endpoints will be all-cause mortality and median days to
      recovery.
    
  